论文部分内容阅读
天士力是我国中药现代化进程中的典范公司,主打产品复方丹参滴丸处于成熟期,销售收入有望平稳增长。公司开始脱离单一品种发展阶段,形成心脑血管治疗药物、抗菌病毒药物系列多个药物共同发展的局面。预计未来三年每股收益0.68元、0.83元、1.06元,12个月目标价21元,投资评级“买入”。
Tasly is a model company in the process of modernization of traditional Chinese medicine in China. Its main product, Compound Danshen Dripping Pills, is in its mature stage and its sales revenue is expected to grow steadily. The company began to break away from the development stage of a single variety to form a common development situation for cardiovascular drugs and anti-viral drugs. Expected earnings per share for the next three years 0.68 yuan, 0.83 yuan, 1.06 yuan, 12-month target price of 21 yuan, investment rating “buy.”